medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2014, Number 4

<< Back Next >>

Rev Mex Patol Clin Med Lab 2014; 61 (4)

System for assessment and risk prevention in the process of obtaining and managing growth factors derived from platelets

Calderón-Garcidueñas ED, Gómez-Morales E, Espinosa-Viveros A, Ortiz-Calderón JP, Radillo-González A

Language: Spanish
References: 18
Page: 205-210
PDF size: 157.50 Kb.


ABSTRACT

Applications of cell therapy in general, and growth factors derived from platelets (FCP) in particular, have been increasing in recent years. However, there is not a systematic protocol that allows to evaluate and detect risk factors in the process of obtention and application of FCP. The objectives of this work are: 1) To propose a system of risk assessment in the process of obtaining and managing the FCP, 2) To apply this system in a convenience sample of patients, to evaluate the implementation. Methodology: We analyzed the processes and identified six points in the system. System was applied in 188 patients. Results: The points of the system include: 1) patient selection, 2) clinical evaluation, 3) sample collection, processing and preservation, 4) product validation, 5) implementation and monitoring FCP and 6) adverse events. 25 incidents were documented in 188 patients (13.2%). Conclusion: The proposed system with six stages, proved to be functional and easy to apply.


REFERENCES

  1. Amable PR, Carias RB, Teixeira MV, da Cruz Pacheco I, Corrêa do Amaral RJ, Granjeiro JM et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013; 4 (3): 67.

  2. Sampson S, Reed M, Silvers H, Meng M, Mandelbaum B. Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: a pilot study. Am J Phys Med Rehabil. 2010; 89: 961-969.

  3. Simonpieri A, Del Corso M, Vervelle A et al. Current knowledge and perspectives for the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in oral and maxillofacial surgery part 2: Bone graft, implant and reconstructive surgery. Curr Pharm Biotechnol. 2012; 13 (7): 1231-1256.

  4. Mishra A, Harmon K, Woodall J, Vieira A. Sports medicine applications of platelet rich plasma. Curr Pharm Biotechnol. 2012; 13 (7): 1185-1195.

  5. Alsousou J, Ali A, Willett K, Harrison P. The role of platelet-rich plasma in tissue regeneration. Platelets. 2013; 24 (3): 173-182.

  6. Trink A, Sorbellini E, Bezzola P, Rodella L, Rezzani R, Ramot Y et al. A randomized, double-blind, placebo and active-controlled, half-head study to evaluate the effects of platelet rich plasma on alopecia areata. Br J Dermatol. 2013; 169 (3): 690-694. doi: 10.1111/bjd.12397.

  7. Valente Duarte de Sousa IC, Tosti A. New investigational drugs for androgenetic alopecia. Expert Opin Investig Drugs. 2013; 22 (5): 573-589.

  8. Recommendations of CDC, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation. Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients. Biol Blood and Marrow Transplant. 2000; 6 (6a): 673-682.

  9. Arroyo-Pérez JA. Prevalencia del virus de la hepatitis B en donadores de sangre mexicanos. Revista Médica del Hospital General de México. 2010; 73 (2): 83-87.

  10. Velasco-Castrejon O, Valdespino JL, Tapia-Conyer R et al. Seroepidemiología de la enfermedad de Chagas en México. Salud Pública Méx. 1992; 34 (2): 186-196.

  11. NORMA Oficial Mexicana NOM-168-SSA1-1998. Del expediente clínico.

  12. NORMA Oficial Mexicana NOM-253-SSA1-2012. Para la disposición de sangre humana y sus componentes con fines terapéuticos.

  13. FACT-JACIE International Standards For Cellular Therapy Product Collection, Processing, and Administration Fifth Edition 2011.

  14. Anitua E, Sánchez M, Orive G, Andía I. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials. 2007; 28 (31): 4551-4560.

  15. Córdova PVH, Vargas VP, Vega LC. Agregometría plaquetaria: el estudio de la agregación de las plaquetas y la disfunción plaquetaria. Med Int Mex. 2011; 27 (1): 58-74.

  16. Otero-López MJ, Alonso-Hernández P, Maderuelo-Fernández JA, Garrido-Corro B, Domínguez-Gil A, Sánchez-Rodríguez A. Acontecimientos adversos prevenibles causados por medicamentos en pacientes hospitalizados. Med Clin (Barc). 2006; 126 (3): 81-87.

  17. Aranaz-Andrés JM. Sucesos adversos relacionados con el uso de medicamentos ¿qué podemos aprender? Med Clin (Barc). 2006; 126 (3): 97-98.

  18. Gómez-Morales E, Calderón-Garcidueñas E, Radillo-González A. Aplicaciones y Práctica de la Medicina Transfusional GCIAMT. Primera edición 2012. Tomo II Capítulo 66. Seguridad y calidad, los puntos críticos del soporte transfusional en el trasplante de progenitores hematopoyéticos. ISBN Obra completa: 978-958-46-1552-7.




2020     |     www.medigraphic.com